Spots Global Cancer Trial Database for Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
Official Title: Tumor Infiltrating Lymphocytes in Pediatric Malignant Solid Tumors: A Prospective Biobanking Study and Phase I Clinical Trial
Study ID: NCT06047977
Conditions
Study Description
Brief Summary: Part One of this study will determine the feasibility of creating Tumor-Infiltrating Lymphocyte (TIL) product prospectively from high-risk pediatric solid tumors. Part Two of this study will determine the safety of TIL therapy with lymphodepleting chemotherapy and post-TIL Interleukin-2 in high-risk pediatric solid tumors
Detailed Description:
Keywords
Eligibility
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
Contact Details
Name: Jonathan Metts, MD
Affiliation: Johns Hopkins All Children's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
